Agents for use in the treatment of retinal inflammation
AssigneesSorbonne Universite, Centre National De La Recherche Scientifique
InventorsFlorian Sennlaub, Xavier Guillonneau, Olivier Levy, José-Alain Sahel
Life of this patent
Estimating the term…
Abstract
The present invention relates to preventive and/or therapeutic agents for use in the treatment of retinal inflammation, and more specifically of Age-related macular degeneration and Retinitis pigmentosa, wherein said agents are selected from an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.
Claims8
A method for treating retinal inflammation in a subject in need thereof, comprising administering to the subject an IL-6 inhibitor as an active ingredient, wherein said retinal inflammation comprises atrophic age-related macular degeneration (AMD) and retinitis pigmentosa and is not associated with neovascularization.
Dependencies are inferred from the claim text.